. Author manuscript; available in PMC: 2022 Jun 13.

Published in final edited form as: Neurogastroenterol Motil. 2021 Sep 17;34(5):e14265. doi: 10.1111/nmo.14265

Table 6.

Prevalence of clinical features of the overlap cohorts in aggregate, compared to the population of IBS with no overlapping MCD

Variables		IBS+ Urticaria (N=23340); N (%)	IBS+MCM (N=60); N (%)	IBS+NMM (N=90); N (%)	IBS+IU (N=2170); N (%)	IBS+MCAS (N=92); N(%)	IBS without MCD (N=599,500); N (%)
ComorbidCondition	Contact dermatitis	9130 (39) (P<0.0001) ^*	10 (17)	20 (22)	840 (39) ^*	12 (13)	84230 (14)
	Allergic rhinitis	11280 (48) ^*	20 (33) ^*	40 (44) ^*	1210 (56) ^*	36 (39) ^*	149650 (25)
	Eczema	9230 (39) ^*	10 (17) ^*	20 (22)	870 (40) ^*	12 (13)	84890 (14)
	Allergic asthma (IgE mediated)	1210 (5) ^*	<10 (<17)	<10 (<11)	140 (6)	N/A	11100 (2)
	Asthma	7930 (34) ^*	30 (50) ^*	30 (33) ^*	770 (35) ^*	34 (37) ^*	120440 (20)
	Food allergy	3770 (16) ^*	20 (33) ^*	20 (22) ^*	420 (19) ^*	24 (26) ^*	45230 (8)
	Drug allergy	15560 (66) ^*	50 (83) ^*	60 (67) ^*	1400 (65) ^*	26 (28) ^*	300600 (50)
	Angioedema	1430 (6) ^*	<10 (<17)	10 (11)	310 (14) ^*	7 (8) ^*	4282 (<1)
	Major depressive disorder	9010 (38) ^*	20 (33) ^*	30 (33) ^*	850 (39) ^*	35 (38) ^*	159680 (27)
	Anxiety disorder	12420 (53) ^*	30 (50) ^*	50 (56) ^*	1150 (53) ^*	58 (63) ^*	219410 (37)
	Migraine	6930 (30) ^*	20 (33) ^*	30 (33) ^*	640 (29) ^*	39 (42) ^*	105560(18)
	Interstitial cystitis	510 (2) ^*	0 (0)	<10 (<11)	50 (2)	N/A	7280 (1)
Procedure History	Delayed hypersensitivity skin test	3160 (13) ^*	<10 (<17)	<10 (<11)	370 (17)	N/A	31530 (5)
	Food IgE level	540 (2) ^*	0 (0)	0 (0)	90 (4) ^*	0 (0)	2070 (<1)
	Food IgG level	110 (0)	<10 (<17)	0 (0)	<10 (<1)	0 (0)	1210 (0)
	Colonoscopy	11690 (50) ^*	20 (33)	30 (33)	1110 (51) ^*	5 (5)	233060 (39)
	Upper endoscopy	8120 (35) ^*	30 (50) ^*	30 (33) ^*	790 (36) ^*	0 (0)	144510 (24)
	Biopsy of skin	2630 (11) ^*	<10 (<17)	10 (11) ^*	320 (15) ^*	0 (0)	29510 (5)
	Endoscopic biopsy	11250 (48) ^*	30 (50) ^*	30 (33)	1100 (51) ^*	0 (0)	203950 (34)
Medication Exposures	MC stabilizer	1730 (7) ^*	20 (33) ^*	20 (22) ^*	200 (9) ^*	5 (5)	16360 (3)
	Antispasmodic	13260 (57) ^*	30 (50)	40 (44)	1200 (55) ^*	0 (0)	258910 (43)
	Antidiarrheal	3140 (13) ^*	<10 (<17)	<10 (<11)	270 (12)	2 (2) ^*	57980 (10)
	Prokinetic	6170 (26) ^*	20 (33)	20 (22)	530 (24) ^*	2 (2) ^*	98150 (16)
	Laxative	13230 (56) ^*	30 (50) ^*	50 (56) ^*	1180 (54) ^*	16 (17) ^*	258340 (43)
	Antiemetic	15760 (67) ^*	40 (67)	50 (56)	1390 (64) ^*	17 (18) ^*	310950 (52)
	Antihistamine	20270 (86) ^*	50 (83) ^*	80 (89) ^*	1920 (88) ^*	20 (22) ^*	383440 (64)

and bold font indicates P<0.05 for the difference between the overlap IBS+MCD cohort compared to IBS without MCD

MCD mast cell disorder; IBS irritable bowel syndrome; MCM mast cell malignancy; NMM Non-malignant mastocytosis; IU idiopathic urticaria; MCAS mast cell activation syndrome